Altimmune, Inc. (NASDAQ:ALT) Short Interest Up 14.9% in April

Altimmune, Inc. (NASDAQ:ALT) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 20,370,000 shares, a growth of 14.9% from the March 31st total of 17,730,000 shares. Based on an average daily volume of 4,690,000 shares, the short-interest ratio is currently 4.3 days.

Institutional Investors Weigh In On Altimmune

Large investors have recently bought and sold shares of the business. WealthPlan Investment Management LLC purchased a new position in Altimmune in the 3rd quarter worth about $31,000. FNY Investment Advisers LLC bought a new position in Altimmune during the 4th quarter worth about $35,000. Quantbot Technologies LP bought a new position in Altimmune during the 3rd quarter worth about $40,000. Miracle Mile Advisors LLC purchased a new stake in shares of Altimmune in the 3rd quarter worth approximately $44,000. Finally, Russell Investments Group Ltd. boosted its stake in shares of Altimmune by 1,150.9% during the fourth quarter. Russell Investments Group Ltd. now owns 4,303 shares of the company’s stock valued at $48,000 after purchasing an additional 3,959 shares in the last quarter. Institutional investors own 78.05% of the company’s stock.

Wall Street Analyst Weigh In

ALT has been the subject of several analyst reports. HC Wainwright reduced their target price on shares of Altimmune from $15.00 to $12.00 and set a “buy” rating for the company in a report on Monday, April 1st. B. Riley reiterated a “buy” rating and issued a $20.00 price target on shares of Altimmune in a research note on Thursday, March 28th. Guggenheim downgraded Altimmune from a “buy” rating to a “neutral” rating in a research report on Monday. Finally, The Goldman Sachs Group started coverage on Altimmune in a research report on Wednesday, January 24th. They set a “neutral” rating and a $13.00 target price for the company.

Altimmune Stock Performance

Shares of NASDAQ:ALT opened at $6.40 on Tuesday. The firm has a market cap of $453.37 million, a price-to-earnings ratio of -3.88 and a beta of 0.05. The firm has a fifty day moving average price of $9.24 and a 200 day moving average price of $7.61. Altimmune has a fifty-two week low of $2.09 and a fifty-two week high of $14.84.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Wednesday, March 27th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.02. Altimmune had a negative return on equity of 44.77% and a negative net margin of 20,780.75%. The business had revenue of $0.04 million during the quarter. As a group, research analysts predict that Altimmune will post -1.52 earnings per share for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.